Share This Page
Suppliers and packagers for generic pharmaceutical drug: ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
✉ Email this page to a colleague
ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
Enalapril Maleate and Hydrochlorothiazide: Key API Suppliers and Patent Landscape
This report identifies leading suppliers of Enalapril Maleate and Hydrochlorothiazide Active Pharmaceutical Ingredients (APIs) and examines the patent landscape for these widely prescribed medications. The analysis focuses on identifying current manufacturers, assessing patent expiration timelines, and highlighting potential generic entry points.
Who Are the Primary Manufacturers of Enalapril Maleate?
Enalapril Maleate is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure. The global supply chain for this API is characterized by a mix of established and emerging manufacturers, primarily located in India and China.
Key Enalapril Maleate API Suppliers:
- Sun Pharmaceutical Industries Ltd. (India): A global pharmaceutical company with a significant API manufacturing division, Sun Pharma is a major producer of Enalapril Maleate, supplying it to both regulated and emerging markets. Its manufacturing facilities adhere to international quality standards, including US FDA and EMA approvals. [1]
- Lupin Ltd. (India): Another prominent Indian pharmaceutical firm, Lupin manufactures and exports Enalapril Maleate API. The company has a strong regulatory track record and operates multiple API production sites certified by global health authorities. [2]
- Dr. Reddy's Laboratories Ltd. (India): Dr. Reddy's is a diversified pharmaceutical company with a robust API business. It is a significant supplier of Enalapril Maleate, focusing on quality and cost-effectiveness. [3]
- Granules India Ltd. (India): Granules India is a specialist in the production of APIs, including cardiovascular drugs. Enalapril Maleate is a key product in its portfolio, with a focus on large-scale manufacturing. [4]
- Aurobindo Pharma Ltd. (India): Aurobindo is a vertically integrated pharmaceutical company with substantial API manufacturing capabilities. It supplies Enalapril Maleate globally, leveraging its extensive regulatory experience. [5]
- Qilu Pharmaceutical Co., Ltd. (China): Qilu Pharmaceutical is a major Chinese pharmaceutical enterprise that produces a wide range of APIs, including Enalapril Maleate, serving both domestic and international markets. [6]
- Hisun Pharmaceutical Co., Ltd. (China): Hisun Pharmaceutical is another significant Chinese manufacturer of APIs. Enalapril Maleate is part of its portfolio, supported by its investment in R&D and quality control. [7]
These companies often supply Enalapril Maleate to generic drug manufacturers for formulation into finished dosage forms. The pricing and availability can fluctuate based on raw material costs, regulatory compliance, and global demand.
Who Are the Primary Manufacturers of Hydrochlorothiazide?
Hydrochlorothiazide (HCTZ) is a thiazide diuretic used to treat high blood pressure and edema. Its production is concentrated among a similar set of global API manufacturers, with a strong presence in Asia.
Key Hydrochlorothiazide API Suppliers:
- Sun Pharmaceutical Industries Ltd. (India): As with Enalapril Maleate, Sun Pharma is a significant producer of Hydrochlorothiazide API, catering to a global customer base. [1]
- Lupin Ltd. (India): Lupin also manufactures and supplies Hydrochlorothiazide API, benefiting from its established manufacturing infrastructure and regulatory approvals. [2]
- Dr. Reddy's Laboratories Ltd. (India): Dr. Reddy's produces Hydrochlorothiazide API, ensuring supply for its own formulations and for external customers. [3]
- Granules India Ltd. (India): Granules India is a key supplier of Hydrochlorothiazide, emphasizing high-volume production and competitive pricing. [4]
- Aurobindo Pharma Ltd. (India): Aurobindo Pharma's API division includes Hydrochlorothiazide, contributing to its broad spectrum of pharmaceutical ingredients. [5]
- Zhejiang Huahai Pharmaceutical Co., Ltd. (China): Huahai Pharmaceutical is a leading Chinese API manufacturer with a strong presence in diuretics. Hydrochlorothiazide is a core product, produced under strict quality standards. [8]
- API Corporation (Japan): While less dominant in volume compared to Indian and Chinese manufacturers, some Japanese companies also produce high-quality Hydrochlorothiazide API for specialized markets. [9]
- Shanxi Zhongren Chemical Co., Ltd. (China): This Chinese company is known for its production of various APIs, including Hydrochlorothiazide, serving various global markets. [10]
The supply dynamics for Hydrochlorothiazide are similar to Enalapril Maleate, with price and availability influenced by manufacturing costs, regulatory landscapes, and market demand.
What is the Patent Status of Enalapril Maleate?
Enalapril Maleate was first patented by Merck & Co. in the early 1980s. As a molecule that has been in the market for decades, its primary composition of matter patents have long expired.
Enalapril Maleate Patent Expiration:
- Original Composition of Matter Patent: The foundational patent for enalapril maleate has expired globally. The original patent application, US4374829 A, was filed in 1979 and granted in 1983. [11]
- Formulation Patents: While the active ingredient itself is off-patent, specific improved formulations or delivery systems for enalapril maleate may still be protected by patents. These patents typically have shorter lifespans and are often related to extended-release versions, specific salt forms, or combination therapies. For example, patents might cover specific polymorphic forms of enalapril maleate that offer enhanced stability or bioavailability.
- Combination Therapy Patents: Enalapril Maleate is frequently combined with other active ingredients, such as diuretics (e.g., Hydrochlorothiazide) or calcium channel blockers. Patents protecting these specific fixed-dose combinations would have their own expiration dates, distinct from the enalapril maleate patent. For instance, patents for the combination drug Enalapril-HCTZ would have a separate lifecycle.
The absence of a valid composition of matter patent for Enalapril Maleate allows for widespread generic manufacturing. Competition among API suppliers and generic drug manufacturers primarily drives market pricing and accessibility.
What is the Patent Status of Hydrochlorothiazide?
Hydrochlorothiazide is an older drug, first synthesized in the late 1950s. Its original patent protection has long expired, making it a widely available generic API.
Hydrochlorothiazide Patent Expiration:
- Original Composition of Matter Patent: The patent for Hydrochlorothiazide expired in the late 1970s. Its initial development and patenting predate the modern pharmaceutical patenting era for many of its therapeutic uses. [12]
- Process Patents: While the molecule is off-patent, patents may exist for novel or significantly improved methods of synthesizing Hydrochlorothiazide. These process patents can provide a competitive advantage to manufacturers who utilize proprietary synthesis routes, potentially offering higher purity or lower production costs. However, their impact on market entry is less restrictive than composition of matter patents.
- Formulation Patents: Similar to Enalapril Maleate, specific formulations of Hydrochlorothiazide, such as extended-release tablets or unique combinations, could be covered by patents. These patents would protect the specific dosage form or combination, not the active ingredient itself.
The long-standing expiration of the composition of matter patent for Hydrochlorothiazide means that the market is highly competitive, driven by cost-effective manufacturing and established supply chains.
How Do Enalapril Maleate and Hydrochlorothiazide Patents Affect Generic Competition?
The patent landscape for both Enalapril Maleate and Hydrochlorothiazide overwhelmingly favors generic competition.
Impact of Patents on Generic Competition:
- Lack of Composition of Matter Barriers: For both APIs, the primary barriers to generic entry—composition of matter patents—have expired. This allows any manufacturer meeting regulatory requirements to produce and sell these APIs.
- Focus on Manufacturing Efficiency and Quality: Competition among generic API suppliers centers on production cost, purity, consistency, and regulatory compliance. Manufacturers with efficient synthesis processes and strong quality control systems gain a competitive edge.
- Role of Formulation Patents: The primary remaining patent-related influence on these drugs comes from patents on specific formulations or fixed-dose combinations. A patent on a novel formulation of Enalapril Maleate-Hydrochlorothiazide, for example, could prevent generic versions of that specific formulation from entering the market until that patent expires. However, it would not prevent the individual APIs from being manufactured and formulated into generic versions of the original products.
- Regulatory Exclusivity: While not patent-related, regulatory exclusivities granted for New Chemical Entities (NCEs) or significant new uses do not apply here, as these are established drugs.
- Bioequivalence: Generic drug manufacturers seeking to market finished dosage forms must demonstrate bioequivalence to the reference listed drug. This is a regulatory requirement, not a patent-related hurdle.
In summary, the mature patent status of Enalapril Maleate and Hydrochlorothiazide ensures a highly competitive generic market, driven by manufacturing capabilities and regulatory adherence rather than patent protection for the active ingredients.
Key Takeaways
- Major suppliers of Enalapril Maleate and Hydrochlorothiazide APIs are concentrated in India and China, with companies like Sun Pharma, Lupin, Dr. Reddy's, Granules India, Aurobindo Pharma, and Chinese firms like Qilu Pharmaceutical and Zhejiang Huahai Pharmaceutical being prominent.
- The composition of matter patents for both Enalapril Maleate and Hydrochlorothiazide have expired globally, opening the door for extensive generic competition.
- While the APIs themselves are off-patent, patents may still exist for specific formulations, manufacturing processes, or fixed-dose combinations of these drugs, potentially creating niche market exclusivity.
- Generic competition for Enalapril Maleate and Hydrochlorothiazide is primarily driven by manufacturing efficiency, quality control, cost-effectiveness, and regulatory compliance, rather than patent protection.
FAQs
-
Are there any active patents that prevent the manufacturing of Enalapril Maleate API? No, the primary patents covering the composition of matter for Enalapril Maleate have expired. Manufacturing is generally permitted, provided regulatory standards are met.
-
Can companies still patent new uses for Hydrochlorothiazide? While the original patent on Hydrochlorothiazide has expired, companies can seek patents for new therapeutic uses or novel formulations if they meet the criteria of novelty, inventiveness, and industrial applicability. However, these patents would not prevent the generic sale of existing approved uses.
-
How do the expiration dates of patents for combination drugs like Enalapril-HCTZ differ from the individual API patents? Patents for combination drugs have their own independent expiration dates, based on the filing and grant dates of the specific patent covering that combination. These dates can be significantly later than the expiration of the original API patents, potentially extending market exclusivity for the specific combination product.
-
What regulatory hurdles must API suppliers overcome to provide Enalapril Maleate and Hydrochlorothiazide to the US market? Suppliers must comply with FDA regulations, including Good Manufacturing Practices (GMP). API manufacturers typically need to file Drug Master Files (DMFs) with the FDA, which contain detailed information about the manufacturing process, quality control, and stability of the API.
-
Are there significant differences in API quality among the major suppliers of Enalapril Maleate and Hydrochlorothiazide? While all major suppliers must meet pharmacopeial standards (e.g., USP, EP), variations in manufacturing processes can lead to differences in impurity profiles or physical characteristics. Pharmaceutical companies selecting API suppliers conduct rigorous quality assessments and audits to ensure consistency and compliance with their specific product requirements.
Citations
[1] Sun Pharmaceutical Industries Ltd. Annual Report. (Various Years). [2] Lupin Ltd. Annual Report. (Various Years). [3] Dr. Reddy's Laboratories Ltd. Annual Report. (Various Years). [4] Granules India Ltd. Annual Report. (Various Years). [5] Aurobindo Pharma Ltd. Annual Report. (Various Years). [6] Qilu Pharmaceutical Co., Ltd. Company Website. (Accessed October 26, 2023). [7] Hisun Pharmaceutical Co., Ltd. Annual Report. (Various Years). [8] Zhejiang Huahai Pharmaceutical Co., Ltd. Annual Report. (Various Years). [9] API Corporation (Japan) Product Catalog. (Accessed October 26, 2023). [10] Shanxi Zhongren Chemical Co., Ltd. Product Listings. (Accessed October 26, 2023). [11] United States Patent US4374829 A. (1983). Enalapril maleate patent. [12] Historical pharmaceutical patent records indicate the expiration of Hydrochlorothiazide's primary composition of matter patents in the late 1970s. Specific patent numbers and filing dates are widely available through patent databases such as Google Patents or USPTO.
More… ↓
